Prognose

Analytikernes gennemsnitlige kursmål er 169,65 € (+52,48 %). Medianen er 168,05 € (+51,04 %).

Køb	33
Behold	1
Sælg	1

Nyheder Til nyhedsfeedet

Insmed flagged as largest detractor by Artisan despite strong Brinsupri launch

Artisan Global Opportunities said Insmed was its biggest detractor in Q2 after trimming the position, citing Q1 sales modestly below elevated expectations due to concerns around discontinuation, therapy continuation and seasonality. The firm still views BRINSUPRI®'s rapid launch and uptake as encouraging and believes the therapy is on track for blockbuster-level sales and remains well tolerated. Insmed closed at $121.51 on Sept 1, returned 25.42% over the past month, is down 13.45% over 52 weeks, and has a market capitalization of $27.14 billion. » Mere på finance.yahoo.com
Japan grants Insmed approval for lung drug Brensocatib

Japan’s Ministry of Health has approved BRINSUPRI (Brensocatib 25 mg) from Insmed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. The once-daily oral therapy is the first treatment approved in Japan for NCFB and complements existing approvals in the US and Europe. The decision is based on the phase-3 ASPEN study, which showed a reduction in pulmonary exacerbations and positive secondary endpoints over 52 weeks; common adverse events included COVID-19, nasopharyngitis, cough and headache. » Mere på de.investing.com
Insmed raises annual forecast after strong Brinsupri sales

Insmed reports strong Q2 figures and a jump in sales of its lung drug Brinsupri, whose revenue rose quarter-on-quarter by 48.7% to $309.2 million. In response, management raised the revenue outlook for 2026 to as much as $1.87 billion, thereby beating consensus estimates. The stock reacted with notable price gains and increased trading volume. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Insmed allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Insmed en omsætning på 372,82 mio. € og et nettoresultat på -11,6 mio. €

(EUR)	juni 2026	YoY
Omsætning	372,82 mio.	309,09 %
Bruttofortjeneste	313,92 mio.	366,36 %
Nettoresultat	-11,6 mio.	95,75 %
EBITDA	12,41 mio.	104,92 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	24,17 mia. €
Antal aktier	216,75 mio.
Højeste/laveste i 52 uger	183,35 € - 77,90 €
Udbytte	Nej
Beta	0,82
P/E (PE Ratio)	-31,49
PEG (PEG Ratio)	-1,25
K/I (PB Ratio)	37,13
P/S (PS Ratio)	24,66

Virksomhedsprofil

Insmed Incorporated, ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Therapien für Patienten mit schweren und seltenen Krankheiten. Das Unternehmen bietet ARIKAYCE für die Behandlung von Mycobacterium avium complex-Lungenerkrankungen als Teil einer antibakteriellen Kombinationsbehandlung für erwachsene Patienten an. Außerdem entwickelt es Brensocatib, einen oralen reversiblen Inhibitor der Dipeptidylpeptidase 1 zur Behandlung von Patienten mit Bronchiektasen und anderen neutrophilen Erkrankungen, sowie Treprostinil Palmitil Inhalationspulver, eine inhalative Formulierung des Treprostinil-Prodrugs Treprostinil Palmitil zur Behandlung der pulmonalen arteriellen Hypertonie und anderer seltener Lungenerkrankungen. Insmed Incorporated wurde 1988 gegründet und hat seinen Hauptsitz in Bridgewater, New Jersey.